Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study

References

• Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016;5(1):1197. doi:10.1186/s40064-016-2660-0.
   PubMedGoogle Scholar
• Kossai M, Leary A, Scoazec J-Y, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1–2):41–11. doi:10.1159/000479006.
   PubMed Web of Science ®Google Scholar
• Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10(1):174. doi:10.1186/s13045-017-0541-9.
   PubMedGoogle Scholar
• Schwab CL, English DP, Roque DM, Pasternak M, Santin AD. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy. 2014;6(12):1279–1293. doi:10.2217/imt.14.90.
   PubMed Web of Science ®Google Scholar
• Sang W, Zhang Z, Dai Y, Chen X. Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev. 2019;48(14):3771–3810. doi:10.1039/c8cs00896e.
   PubMed Web of Science ®Google Scholar
• Drakes ML, Stiff PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel). 2018:10. doi:10.3390/cancers10090302.
   Web of Science ®Google Scholar
• Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006;125(3):451–458. doi:10.1309/15b66dqmfyym78cj.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny ALJensen A, et al. Dose-response association of cd8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. Jama Oncol. 2017;3:e173290. doi: 10.1001/jamaoncol.2017.3290.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I-M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747. doi:10.1016/j.ajpath.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Kuwada K, Kagawa S, Yoshida R, Sakamoto S, Ito A, Watanabe M, Ieda T, Kuroda S, Kikuchi S, Tazawa H, et al. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):307. doi:10.1186/s13046-018-0981-2.
   PubMedGoogle Scholar
• Oh E, Hong J, Yun CO. Regulatory T cells induce metastasis by activating Tgf-beta and enhancing the epithelial-mesenchymal transition. Cells. 2019:8. doi:10.3390/cells8111387.
   PubMed Web of Science ®Google Scholar
• Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018;9(1):3503. doi:10.1038/s41467-018-05992-x.
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016;22(3):609–620. doi:10.1158/1078-0432.CCR-15-0876.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–257. doi:10.1016/S0140-6736(14)62223-6.
   PubMed Web of Science ®Google Scholar
• Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, Cliby WA, Oberg AL, Kaufmann SH, Goode EL, et al. Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clin Cancer Res. 2017;23(15):4077–4085. doi:10.1158/1078-0432.CCR-17-0246.
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Ali HR, Chlon L, Pharoah PDP, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016:13. doi:10.1371/journal.pmed.1002194.
   Web of Science ®Google Scholar
• Shen S, Wang G, Zhang R, Zhao Y, Yu H, Wei Y, Chen F. Development and validation of an immune gene-set based prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318–326. doi:10.1016/j.ebiom.2018.12.054.
   PubMed Web of Science ®Google Scholar
• Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29. doi:10.1186/gb-2014-15-2-r29.
   PubMed Web of Science ®Google Scholar
• Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279–290. doi:10.1158/1078-0432.CCR-12-1558.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2019;51(2):411–412. doi:10.1016/j.immuni.2019.08.004.
   PubMed Web of Science ®Google Scholar
• Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1–2):334–347 e312. doi:10.1016/j.cell.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang Y, Yang Z, Peng H, Wei R, Wang C, Feng M. Tunneling nanotubular expressways for ultrafast and accurate M1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma. ACS Nano. 2019;13(2):1078–1096. doi:10.1021/acsnano.8b08872.
   PubMed Web of Science ®Google Scholar
• Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel T, Emde M, Schmidleithner L, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–288. doi:10.1016/j.immuni.2014.01.006.
   PubMed Web of Science ®Google Scholar
• Cho U, Kim B, Kim S, Han Y, Song YS. Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-κB activation. Mol Carcinog. 2018;57(2):235–242. doi:10.1002/mc.22750.
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang S-J, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179. doi:10.1038/srep15179.
   PubMed Web of Science ®Google Scholar
• Coffre M, Placek K, Maiella S, Bianchi E, Rogge L. Single-cell analysis techniques reveal a striking heterogeneity of human CD4+ T cell subsets. J Transl Med. 2010:8. doi:10.1186/1479-5876-8-s1-o5.
   PubMedGoogle Scholar
• Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.00561.
   PubMed Web of Science ®Google Scholar
• K F, K Y, T O. Overview of LAG-3-expressing, IL-10-producing regulatory T cells. Curr Top Microbiol Immunol. 2017;17:410. doi:10.1007/82_2017_59.
   Google Scholar
• Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–18543. doi:10.1073/pnas.0509182102.
   PubMed Web of Science ®Google Scholar
• Corradetti B, Pisano S, Conlan RS, Ferrari FM. Nanotechnology and immunotherapy in ovarian cancer: tracing new landscapes. J Pharmacol Exp Ther. 2019;370(3):636–646. doi:10.1124/jpet.118.254979.
   PubMed Web of Science ®Google Scholar
• van Furth R, Raeburn JA, van Zwet TL. Characteristics of human mononuclear phagocytes. Blood. 1979;54(2):485–500. doi:10.1182/blood.V54.2.485.485.
   PubMed Web of Science ®Google Scholar
• Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176–194. doi:10.1084/jem.20181170.
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24(1):99–146. doi:10.1146/annurev.immunol.24.021605.090737.
   PubMedGoogle Scholar
• Mills CD. Anatomy of a discovery: m1 and m2 macrophages. Front Immunol. 2015;6:212. doi:10.3389/fimmu.2015.00212.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. 2017;8(9):15621–15631. doi:10.18632/oncotarget.14919.
   PubMedGoogle Scholar
• Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, Rahimi K, Shaw PA, Clarke BA, Nelson BH, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925–934. doi:10.1158/1078-0432.CCR-16-1433.
   PubMed Web of Science ®Google Scholar